Full Spectrum Genetics deal
Full Spectrum said it extended a 2012 deal with an undisclosed pharma to engineer and analyze variants of specified molecules using Full Spectrum's MapEng platform. The original deal consisted of generating multiple therapeutic protein and antibody candidates. The extension will utilize the MapEng platform to provide information on the specificity of the therapeutic protein variants discovered during the project. The pharma has worldwide rights to any products arising from the deal. Full Spectrum said it is eligible for two cash payments upon completion of the extension. The company declined to disclose details. In May, the company received two milestone payments for completing the two original projects under the deal (see BioCentury, May 13 & May 20). ...